Daniel Pollyea retweetet
Such a great time in La Jolla at the 30th Annual @MedscapeOnc #ALFLive26 spending time with great friends & colleagues! Will miss this sunset & view! @beatalleukemia @KatieLaiMD_MPH
English
Daniel Pollyea
1.3K posts
Daniel Pollyea
@DanPollyea
The Leukemologist
Denver, Colorado Beigetreten Ekim 2012
345 Folgt1.7K Follower
Daniel Pollyea retweetet
Excited to share that I have been promoted to Professor of Medicine @UNC_SOM @UNC_Lineberger. This milestone could not have been possible w/o the invaluable mentorship from Judy Karp @hopkinskimmel who instilled in me the passion, motivation & drive to improve outcomes in AML.
English
Daniel Pollyea retweetet
What a great way to end #ALFLive26 with Sasha Perl providing a fantastic overview discussing the pearls (pun intended) and challenges of post-transplant maintenance in AML. @MedscapeOnc
English
Daniel Pollyea retweetet
Fantastic talk to kick off #ALF26 by @MikkaelSekeres on the pitfalls with our prior trials of Aza combinations in HR-MDS.
English
Daniel Pollyea retweetet
Paradigm Results put in perspective by Amir Fathi @MedscapeOnc #ALFLIVE26. Great presentation to follow the @ASH_hematology plenary! Now we are all eagerly awaiting the publication with more details and subset analyses.
English
Daniel Pollyea retweetet
Such an incredible conference highlighting all of the advances and cutting edge therapies for acute leukemia and MDS. Hard to believe this is the 30th annual @MedscapeOnc #ALFLive26 Conference. Kudos to Eytan Stein, @CarrawayHetty & @DanPollyea for running a superb meeting!
English
Daniel Pollyea retweetet
Daniel Pollyea retweetet
We decided to turn curing leukemia into a family pursuit with @samsekeres! #ProudPapa 🥹🎗️🧪news.med.miami.edu/like-father-li… @SylvesterCancer @UMiamiHealth @umiamimedicine @ASH_hematology @JCO_ASCO @ASCO @TaylorJ_MD
English
Daniel Pollyea retweetet
Dr. Uma Borate: Associate Professor@beatalleukemia
Outstanding & thought provoking Grand Rounds by @DanPollyea from @CUCancerCenter discussing Ven resistance in AML therapy. Heartwarming homecoming to his Cbus roots with his proud mom attending his talk ! Look forward to more collaborations & moving the needle for our pts.@OSUCCC_James
English
Daniel Pollyea retweetet
Outstanding & thought provoking Grand Rounds by @DanPollyea from
@CUCancerCenter discussing Ven resistance in AML therapy. Heartwarming homecoming to his Cbus roots with his proud mom attending his talk ! Look forward to more collaborations & moving the needle for our pts.@OSUCCC_James
English
Daniel Pollyea retweetet
Amazing! Can’t imagine how proud mama @DanPollyea is.
Dr. Uma Borate: Associate Professor@beatalleukemia
Outstanding & thought provoking Grand Rounds by @DanPollyea from @CUCancerCenter discussing Ven resistance in AML therapy. Heartwarming homecoming to his Cbus roots with his proud mom attending his talk ! Look forward to more collaborations & moving the needle for our pts.@OSUCCC_James
English
Daniel Pollyea retweetet
Daniel Pollyea retweetet
English
pubmed.ncbi.nlm.nih.gov/41742869/
Excited about the publication of our long-time coming clinical trial, with @JustinWattsMD @UMiamiHealth. We enrolled newly diagnosed AML patients younger than 60, independent of fitness for intensive chemotherapy, and gave them venetoclax.
English
Daniel Pollyea retweetet
Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy - PubMed - Happy to be part of this study! Congratulations to the team especially @JustinWattsMD and @DanPollyea #leusm pubmed.ncbi.nlm.nih.gov/41742869/
English
Daniel Pollyea retweetet
How do you tackle the toughest hematology cases in the community setting? Moderator Dr. Alexander Perl leads a panel featuring @RahulBanerjeeMD, Sarah Rutherford, Eric Padron, @DanPollyea, and Jeffrey Lancet as they dig into real‑world decision‑making in Challenging Clinical Scenarios in the Community. Starts at 3:45pm.
#NashvilleHeme26
na2.hubs.ly/H03YqgW0
English
Daniel Pollyea retweetet
English
Daniel Pollyea retweetet
Important post-hoc trial data on #HMAVen as bridge to allo-HSCT in IC-ineligible #AMLsm patients:
- approx. 50% survival at 4 yrs post-SCT
- best outcomes in #ELN22 fav and int risk and MRD-neg CR pre-SCT @DanPollyea @PratzKW
Keith W Pratz MD@PratzKW
Happy to share the long term outcomes of patients who underwent Allo transplant on the Phase 1b and VIALE- A trials of HMA with Venetoclax. 33 patients with median age of 69 were found to have median survival of 29.9 months post Allo(median fu of 31.6 mo). onlinelibrary.wiley.com/doi/10.1002/aj…
English
Daniel Pollyea retweetet
🤠 Sheriff @lymphomaphilia is drawing the line at high noon for three high‑stakes Showdown Debates—CLL, AML, and Myeloma—at #NashvilleHeme26, Feb 26–28 in Nashville, TN. With 60+ faculty fixin' to ride in, he’ll keep the draw clean and the count fair. Don't miss it! Free registration with code FREECME ➜ na2.hubs.ly/H031H-X0
#HemeTwitter #MedEd #CME
English
Daniel Pollyea retweetet
🤠 WANTED: A heme showdown where the data does the talking. Debate Showdown: AML edition! Starring: @DanPollyea & @LancetJeff. Sheriff on duty: @lymphomaphilia. Free registration with code FREECME. Full agenda & schedule ➜ na2.hubs.ly/H030pvy0
#AML #NashvilleHeme26 #HemeTwitter #MedEd #CME
English